Sorafenib or anthracycline‐based chemotherapy for progressive desmoid tumors

蒽环类 医学 索拉非尼 内科学 养生 不利影响 实体瘤疗效评价标准 肿瘤科 外科 化疗 癌症 临床研究阶段 乳腺癌 肝细胞癌
作者
Philippos Apolinário Costa,Arshia Arora,Y. Fernandez,Irvin Yi,Baylee F. Bakkila,Heng Tan,Priscila Barreto Coelho,Leticia Campoverde,Nicole Hardy,Steven Bialick,Andrea P. Espejo-Freire,Gina Z. D’Amato,Yu-Cherng Chang,Jacob Peter Mesenger,Ty K. Subhawong,Andrew Haims,Michael E. Hurwitz,Kelly Olino,Kiran K. Turaga,Hari A. Deshpande,Jonathan C. Trent
出处
期刊:Cancer [Wiley]
标识
DOI:10.1002/cncr.35647
摘要

Abstract Background Desmoid tumors can cause morbidity due to local invasion, potentially being fatal when fast growth compromises vital structures. In this context, a timely treatment response is required. This study aims to compare the activity of sorafenib and anthracycline‐containing regimens during the first year of treatment. Methods The authors conducted a multi‐institutional retrospective analysis of desmoid tumor patients treated with either sorafenib or an anthracycline‐containing regimen over 1 year. The primary end point was the overall response rate (ORR). The secondary end points were time to response (TTR), progression‐free survival (PFS), and adverse events. Results From 2005 to 2022, 80 patients received sorafenib and 51 received an anthracycline‐containing regimen with similar baseline characteristics. The 1‐year ORR was 37% for anthracycline and 13% for sorafenib ( p = .016). Median best response was –9% (range, –73 to 51) for anthracycline and –4% (range, –69 to 126) for sorafenib. Median TTR was 5.6 months (95% confidence interval [CI], 3.4–7.8) for anthracycline and 8.7 months (95% CI, 6.3–11.1) for sorafenib ( p = .2). One‐year PFS was 73% (95% CI, 60–86) for anthracycline and 59% (95% CI, 47–71) for sorafenib ( p = .3). Common grade 1–2 adverse events for sorafenib were hand‐foot syndrome (40%), diarrhea (25%), and fatigue (22%); for anthracycline, they were nausea (31%), fatigue (16%), and rash (14%). Grade 3 events were higher in the anthracycline group, 27% versus 14% ( p < .05). Conclusion Anthracycline‐based therapy provided a greater 1‐year response rate than sorafenib but was associated with a higher rate of serious adverse events. Higher‐risk desmoid tumors, which need a more timely response, might benefit from anthracycline‐based therapies, whereas average‐risk tumors could benefit from sorafenib.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
youyuguang完成签到 ,获得积分10
刚刚
1秒前
1秒前
程大大大教授完成签到,获得积分10
1秒前
2秒前
耍酷的白梦完成签到,获得积分10
2秒前
完美的友蕊应助pups采纳,获得10
3秒前
悄悄是心上的肖肖完成签到 ,获得积分10
4秒前
Jackcaosky完成签到 ,获得积分10
4秒前
SYSUer发布了新的文献求助10
4秒前
lkc完成签到,获得积分10
5秒前
陌小千完成签到 ,获得积分10
5秒前
wyblobin完成签到,获得积分10
5秒前
明道若昧完成签到,获得积分10
6秒前
自然千山完成签到,获得积分10
6秒前
在途中发布了新的文献求助10
7秒前
7秒前
Owen应助树袋熊和考拉采纳,获得10
9秒前
潇洒完成签到,获得积分10
9秒前
nater1ver完成签到,获得积分10
10秒前
landiao完成签到,获得积分10
10秒前
剁手党完成签到,获得积分10
10秒前
qsmei2020完成签到,获得积分10
10秒前
holic完成签到,获得积分10
10秒前
杨白秋完成签到,获得积分0
11秒前
zhz完成签到,获得积分10
11秒前
kangshuai完成签到,获得积分10
12秒前
JevonCheung完成签到 ,获得积分10
12秒前
12秒前
机智的天蓉完成签到 ,获得积分10
13秒前
JUZI完成签到,获得积分10
13秒前
早睡完成签到 ,获得积分10
14秒前
yar应助啊哈采纳,获得10
14秒前
幸运的科研小狗完成签到,获得积分10
15秒前
Lynn完成签到,获得积分10
16秒前
正直的魔镜完成签到 ,获得积分10
16秒前
16秒前
米粥饭完成签到,获得积分10
17秒前
ommphey完成签到 ,获得积分10
17秒前
llllt发布了新的文献求助10
17秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Cognitive Neuroscience: The Biology of the Mind 1000
Technical Brochure TB 814: LPIT applications in HV gas insulated switchgear 1000
Immigrant Incorporation in East Asian Democracies 600
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
A Preliminary Study on Correlation Between Independent Components of Facial Thermal Images and Subjective Assessment of Chronic Stress 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3968593
求助须知:如何正确求助?哪些是违规求助? 3513416
关于积分的说明 11167791
捐赠科研通 3248853
什么是DOI,文献DOI怎么找? 1794507
邀请新用户注册赠送积分活动 875170
科研通“疑难数据库(出版商)”最低求助积分说明 804671